Biotech company F-star on Monday said it has entered into a collaboration and license agreement with US drugmaker AbbVie (NYSE: ABBV) to research and develop bispecific antibodies in immuno-oncology.
No financial terms were disclosed.
John Haurum, chief executive officer, said: “We are very excited to be working with AbbVie on these immuno-oncology programmes to develop new bispecific antibodies. Bispecific antibodies are expected to be the cornerstone of the next generation of immuno-oncology products and this collaboration validates our technology as truly novel and differentiated in the space.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze